3705.TW
Strong BuyFull HouseAI screen passYungShin Global Holding Corporation · Healthcare · Taiwan · $469M
TWD 57.10 +0.9% · close 6 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
YungShin Global Holding delivers dependable profitability and resilient returns through its integrated manufacturing of generic pharmaceuticals, veterinary medicines, and consumer health products. Balanced financial strength and steady pricing power in Asian healthcare channels provide enduring fundamental support.
ABOUT YUNGSHIN GLOBAL HOLDING CORPORATION
Read
YungShin Global Holding Corporation is a Taiwanese healthcare group engaged in the R&D, manufacturing, and distribution of a diverse range of generic and branded pharmaceutical products, medical devices, and health supplements. Its competitive advantage lies in its comprehensive product portfolio, strong domestic distribution network, and vertically integrated operations from research to market. This solidifies its position as a key player in Taiwan's pharmaceutical sector.
FINANCIAL SUMMARY (TWD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 7.3B | 7.0B | 8.0B | 8.4B | 4.6% | 7.9B |
| EPS (TWD) | 2.77 | 3.15 | 3.11 | 4.39 | 3.31 | 4.5% | 3.38 |
| Shares | — | 266.4M | 266.4M | 266.4M | 266.4M | 0.0% | 266.4M |
| Debt | — | 1.8B | 1.2B | 1.2B | 1.2B | -13.5% | 1.3B |
| Equity | — | 7.2B | 7.3B | 8.0B | 8.2B | 4.4% | — |
| Op CF | — | 967.2M | 1.2B | 1.4B | 1.5B | 16.1% | 1.4B |
| Inv CF | — | 423.0M | -402.9M | -179.3M | -1.5B | — | — |
| Fin CF | — | -702.2M | -1.2B | -846.1M | -615.7M | — | — |
Calmer than 98% of stocks we rank over the past year (12% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 3705.TW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 3705.TW | YungShin Global Holding Corporation(you) | $469M | 97 | Strong Buy |
| 4105.TWO | TTY Biopharm Company Limited | $612M | 99 | Strong Buy |
| 1720.TW | Standard Chemical & Pharmaceutical Co., Ltd. | $347M | 96 | Strong Buy |
| 1707.TW | Grape King Bio Ltd | $405M | 87 | Strong Buy |
| 4114.TWO | Synmosa Biopharma Corporation | $471M | 58 | Hold |
| 1731.TW | Maywufa Company Ltd. | $87M | 92 | Strong Buy |
| 8432.TWO | TSH Biopharm Corporation Limited | $61M | 100 | Strong Buy |
| 6620.TWO | Handa Pharmaceuticals, Inc. | $633M | 55 | Hold |
| 4746.TW | Formosa Laboratories, Inc. | $182M | 67 | Buy |
| 1760.TW | Panion & Bf Biotech Inc. | $145M | 68 | Buy |
Peer medians: ROE 4.1% · P/E 15.4x · Gross margin 42.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.